Zoetis 碩騰(ZTS) | 美股同學會

鉅亨網

碩騰

ZTS

鉅亨速報 - Factset 最新調查：碩騰ZTS-US的目標價調降至202元，幅度約10.22%

FactSet 最新調查：碩騰ZTS-US目標價調降，最高估值、最低估值、中位數、綜合評級、近5日股價、標普、即時新聞資訊

詳全文

鉅亨網

02月14日 13:40

碩騰

ZTS

鉅亨速報 - Factset 最新調查：碩騰(ZTS-US)EPS預估下修至6.15元，預估目標價為225.00元

FactSet 最新調查：碩騰(ZTS-US)EPS預估下修，預估EPS、預估營收、目標價、歷史獲利表現、即時新聞資訊

詳全文

YahooFinanceBusiness

2024年09月26日 17:34

碩騰

ZTS

Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy

On Thursday, the FDA approved Elanco Animal Health Incorporated’s (NYSE:ELAN) Zenrelia, a once-daily oral JAK inhibitor for the control of pruritus (itching) associated with allergic dermatitis and atopic dermatitis in dogs at least 12 months of age.
Approximately 17 million dogs suffer from aller

詳全文

碩騰

(ZTS)

鉅亨速報 - Factset 最新調查：碩騰ZTS-US的目標價調降至202元，幅度約10.22%

Why Zoetis Stock Took Another Tumble Today

Zoetis gains conditional license for avian flu vaccine in chickens

鉅亨速報 - Factset 最新調查：碩騰(ZTS-US)EPS預估下修至6.15元，預估目標價為225.00元

Zoetis projects 6%-8% organic revenue growth for 2025 with strong companion animal performance (NYSE:ZTS)

Zoetis falls 7% on soft 2025 guidance

Zoetis Non-GAAP EPS of $1.40 beats by $0.06, revenue of $2.3B in-line (NYSE:ZTS)

Phibro raises FY 2025 guidance with Zoetis portfolio integration driving 25% revenue growth (NASDAQ:PAHC)

Zoetis stock dips after FDA notice on Librela (ZTS:NYSE)

Elanco's Dermatology Treatment Secures FDA Approval For Itchy Dogs, Analyst Highlights Label Warnings And Efficacy

碩騰 (ZTS)

碩騰

(ZTS)